Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for prevention of radiation pneumonitis in lung cancer
ChiCTR2500103496Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in radiation pneumonitis (RP) and bronchial carcinoma (2 arms), sponsored by Shandong First Medical University. Primary endpoint: Incidence of grade 2 or higher radiation pneumonitis at 3 months after radiotherapy. Planned start May 2025; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
radiation pneumonitis (RP)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500103496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103496.